Leads Biolabs(09887.HK): Grant of 2,254,691 H-share Awards to 149 Grantees
NewTimeSpace News: On July 1, 2026, Leads Biolabs(09887.HK) issued an announcement stating that under its H-share incentive scheme, the Company granted a total of 2,254,691 share awards to 149 grantees at a nil subscription price. Vesting of such awards is conditional on the achievement of individual performance targets, and the awards are subject to the clawback mechanism set out in the H-share incentive scheme.
As disclosed in the announcement, the awarded shares will be funded by the trustee purchasing existing H-shares via on-market transactions at prevailing market prices in accordance with the Company’s instructions. No new shares will be issued in connection with this grant, and therefore there will be no dilution to existing shareholders’equity interests.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- LEADS BIOLABS-B (09887.HK): Chairman Plans HKD 20M H-Share Purchase
- LEADS BIOLABS-B (09887.HK): Presents LBL-024 Data at Jefferies
- LEADS BIOLABS-B (09887.HK): LBL-047 completes first SLE patient dosing in Phase I Part B
- LEADS BIOLABS-B (09887.HK): LBL-024 data presented at ESMO 2026, 3L EP-NEC median OS 8.7 months
- LEADS BIOLABS-B (09887.HK): Updated LBL-034 Data in RRMM Presented at ESMO